Literature DB >> 19141130

Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007.

Gordon F Schwartz1, Kevin S Hughes, Henry T Lynch, Carol J Fabian, Ian S Fentiman, Mark E Robson, Susan M Domchek, Lynn C Hartmann, Roland Holland, David J Winchester, Benjamin O Anderson, Banu K Arun, Harry Bartelink, Philip Bernard, Bernardo Bonanni, Blake Cady, Krishna B Clough, Stephen A Feig, Sylvia H Heywang-Köbrunner, Anthony Howell, Claudine Isaacs, Daniel B Kopans, Robert E Mansel, Shahla Masood, Juan P Palazzo, Peter I Pressman, Lawrence J Solin, Michael Untch.   

Abstract

A consensus conference including thirty experts was held in April, 2007, to discuss risk factors for breast cancer and their management. Four categories of risk were outlined, from breast cancer "average" through "very high" risk, the latter including individuals with high penetrance BRCA1/2 gene mutations. Guidelines for management of patients in each of these categories were discussed, with the major portion of the conference being devoted to individuals with BRCA1/2 mutations. Prevalence of these mutations in the general populations was estimated to be 1 in 250-500 individuals, with an increased prevalence in Ashkenazic Jews and other founder groups. Risk reduction strategies for these individuals include surveillance, with or without chemoprevention drugs, or surgical procedures to remove the organs at risk, i.e., bilateral mastectomy and/or bilateral salpingo-oophorectomy. These risk reduction strategies were evaluated fully, and recommendations were made for the care of patients in each of the risk categories. These guidelines for patient care were approved by the entire group of experts.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19141130      PMCID: PMC3756316          DOI: 10.1111/j.1524-4741.2008.00665.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  12 in total

1.  A long AAAG repeat allele in the 5' UTR of the ERR-γ gene is correlated with breast cancer predisposition and drives promoter activity in MCF-7 breast cancer cells.

Authors:  C L Galindo; J F McCormick; V J Bubb; D H Abid Alkadem; Long-Shan Li; L J McIver; A C George; D A Boothman; J P Quinn; M A Skinner; H R Garner
Journal:  Breast Cancer Res Treat       Date:  2010-12-10       Impact factor: 4.872

2.  Estimating penetrance from multiple case families with predisposing mutations: extension of the 'genotype-restricted likelihood' (GRL) method.

Authors:  Bernard Bonaïti; Valérie Bonadona; Hervé Perdry; Nadine Andrieu; Catherine Bonaïti-Pellié
Journal:  Eur J Hum Genet       Date:  2010-10-06       Impact factor: 4.246

3.  Performing and Declining PGD: Accounts of Jewish Israeli Women Who Carry a BRCA1/2 Mutation or Partners of Male Mutation Carriers.

Authors:  Efrat Dagan; Daphna Birenbaum-Carmeli; Eitan Friedman; Baruch Feldman
Journal:  J Genet Couns       Date:  2017-03-06       Impact factor: 2.537

4.  Ethical issues in presymptomatic genetic testing for minors: a dilemma in Li-Fraumeni syndrome.

Authors:  Brice Fresneau; Laurence Brugières; Olivier Caron; Grégoire Moutel
Journal:  J Genet Couns       Date:  2012-12-12       Impact factor: 2.537

Review 5.  Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes.

Authors:  Amanda Parkes; Banu K Arun; Jennifer K Litton
Journal:  Oncologist       Date:  2017-05-03

Review 6.  BRCA1-No Matter How You Splice It.

Authors:  Dan Li; Lisa M Harlan-Williams; Easwari Kumaraswamy; Roy A Jensen
Journal:  Cancer Res       Date:  2019-04-16       Impact factor: 12.701

7.  Establishing a program for individuals at high risk for breast cancer.

Authors:  Fernando Cadiz; Henry M Kuerer; Julio Puga; Jamile Camacho; Eduardo Cunill; Banu Arun
Journal:  J Cancer       Date:  2013-07-01       Impact factor: 4.207

8.  General Practitioners and Breast Surgeons in France, Germany, Netherlands and the UK show variable breast cancer risk communication profiles.

Authors:  Claire Julian-Reynier; Anne-Deborah Bouhnik; D Gareth Evans; Hilary Harris; Christi J van Asperen; Aad Tibben; Joerg Schmidtke; Irmgard Nippert
Journal:  BMC Cancer       Date:  2015-04-09       Impact factor: 4.430

9.  Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer.

Authors:  Jong Won Lee; Woochang Lee; Hyun-Ki Kim; Eun Jin Lee; Young-Jae Lee; Jisun Kim; Yongsub Kim; Kyunggon Kim; Shin-Wha Lee; Suhwan Chang; Young Joo Lee; Sail Chun; Byung Ho Son; Kyung Hae Jung; Yong-Man Kim; Won-Ki Min; Sei-Hyun Ahn
Journal:  J Hum Genet       Date:  2020-01-06       Impact factor: 3.172

10.  Hereditary cancer risk assessment: insights and perspectives for the Next-Generation Sequencing era.

Authors:  Israel Gomy; Maria Del Pilar Estevez Diz
Journal:  Genet Mol Biol       Date:  2016-05-13       Impact factor: 1.771

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.